AbstractObjective To explore the influence of body mass index (BMI) changes on the doses to normal tissues and adverse reactions of the lower digestive system and urinary system in the brachytherapy for cervical cancer. Methods Clinical data of 80 cervical cancer patients who received radical radiotherapy in our hospital from January 2020 to February 2021 were retrospectively analyzed. All patients received external beam radiation ± chemotherapy + brachytherapy. The delineation method of target areas and organs at risk (OAR) was determined based on the recommended scheme of GEC‐ESTRO. The target areas included high risk (HR)‐CTV and intermediate risk (IR)‐CTV, and OAR consisted of rectum, sigmoid colon, bladder, and small intestine. The target area dose was evaluated by D90% of the HR‐CTV. The OAR volume dose was evaluated by using D2cm3 Correlation analysis was used to compare the dosimetric relationship between BMI and D2cm3,D1cm3 and D0.1cm3 in bladder, rectum, colon and small intestine. Logistic regression analysis was adopted to analyze the risk factors of acute and late adverse reactions in the lower gastrointestinal system and urinary system. Whether BMI was a risk factor was validated. Results BMI was negatively correlated with the D2cm3、D1cm3、D0.1cm3 of the small intestine (P=0.034, 0.024, 0.034), and the correlation coefficients were -0.240, -0.255, and -0.241, respectively. Logistic regression analysis showed that BMI was not a risk factor for the occurrence of acute and late adverse reactions in the lower gastrointestinal system and urinary system. For every 1 Gy increase of D2cm3、D1cm3、D0.1cm3 in the small intestine, the relative risk of acute adverse reactions in the lower gastrointestinal system was increased by 16.6%, 15.1%,and 12.7%, respectively. Conclusions In brachytherapy for cervical cancer, there is a negative correlation between BMI and D2cm3、D1cm3、D0.1cm3 of the small intestine. As the BMI of patients declines, the radiation dose to the small intestine shows an increasing trend, which may increase the risk of acute adverse reactions in the lower gastrointestinal system.
Fund:National Natural Science Foundation of China (82073331); Project of Science and Technology Department of Jilin Province (20210401138YY); Horizontal Project of Jilin University (2019YX435,2019155)
Zhang Zhaoming,Han Dongmei,Mao Zhuang et al. Effect of body mass index on normal tissue radiation doses and adverse reactions in brachytherapy for cervical cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(9): 805-810.
Zhang Zhaoming,Han Dongmei,Mao Zhuang et al. Effect of body mass index on normal tissue radiation doses and adverse reactions in brachytherapy for cervical cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(9): 805-810.
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209‐249. DOI: 10.3322/caac.21660.
[2] Koh WJ, Abu‐Rustum NR, Bean S, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(1):64‐84. DOI: 10.6004/jnccn.2019.0001.
[3] Wang X, Fan L, Yan W, et al. Comparison of accuracy and long‐term prognosis between computed tomography‐based and magnetic resonance imaging‐based brachytherapy for cervical cancer: a meta‐analysis[J]. J Med Imaging Radiat Oncol, 2020, 64(1):151‐162. DOI: 10.1111/1754‐9485.12984.
[4] Tiberi D, Gruszczynski N, Meissner A, et al.Influence of body mass index and periprostatic fat on rectal dosimetry in permanent seed prostate brachytherapy[J]. Radiat Oncol, 2014, 9(1):93. DOI: 10.1186/1748‐717X‐9‐93.
[5] Lim J, Durbin‐Johnson B, Valicenti R, et al. The impact of body mass index on rectal dose in locally advanced cervical cancer treated with high‐dose‐rate brachytherapy[J]. Brachytherapy, 2013, 12(6):550‐554. DOI: 10.1016/j.brachy.2013.04.006.
[6] von Gruenigen VE, Tian C, Frasure H, et al. Treatment effects, disease recurrence,survival in obese women with early endometrial carcinoma : a gynecologic oncology group study[J]. Cancer, 2006, 107(12):2786‐2791. DOI: 10.1002/cncr.22351.
[7] Haie‐Meder C, Pötter R, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC‐ESTRO working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol, 2005, 74(3):235‐245. DOI: 10.1016/j.radonc.2004.12.015.
[8] K Jensen NB, Pötter R, Spampinato S, et al. Dose‐volume effects and risk factors for late diarrhea in cervix cancer patients after radiochemotherapy with image guided adaptive brachytherapy in the EMBRACE I study[J]. Int J Radiat Oncol Biol Phys, 2021, 109(3):688‐700. DOI: 10.1016/j.ijrobp.2020.10.006.
[9] Pötter R, Haie‐Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image‐based treatment planning in cervix cancer brachytherapy‐3D dose volume parameters and aspects of 3D image‐based anatomy, radiation physics, radiobiology[J]. Radiother Oncol, 2006, 78(1):67‐77. DOI: 10.1016/j.radonc.2005.11.014.
[10] Prescribing, recording,reporting brachytherapy for cancer of the cervix[J]. J ICRU, 2013, 13(1‐2):NP. DOI: 10.1093/jicru/ndw027.
[11] Boyle JM, Craciunescu O, Steffey B, et al. Body mass index, dose to organs at risk during vaginal brachytherapy,the role of three‐dimensional CT‐based treatment planning[J]. Brachytherapy, 2014, 13(4):332‐336. DOI: 10.1016/j.brachy.2013.12.002.
[12] Sabater S, Arenas M, Berenguer R, et al. Body mass index and doses at organs at risk in a mediterranean population treated with postoperative vaginal cuff brachytherapy[J]. Cancer Res Treat, 2015, 47(3):473‐479. DOI: 10.4143/crt.2014.115.
[13] Talluri A K, Yarrama A, Ahamed S, et al.Body mass index versus bladder and rectal doses using 2D planning for patients with carcinoma of the cervix undergoing HDR brachytherapy[J]. Int J Cancer Therap Oncol, 2016, 4(2): 422-422. DOI: 10.14319/ijcto.42.2.
[14] Holloway CL, Macklin EA, Cormack RA, et al. Should the organs at risk be contoured in vaginal cuff brachytherapy?[J]. Brachytherapy, 2011, 10(4):313‐317. DOI: 10.1016/j.brachy.2010.10.005.
[15] Smits A, McGrane J, Lopes A, et al. Radiation‐related toxicities and outcomes in endometrial cancer: are obese women at a disadvantage?[J]. Int J Clin Oncol, 2017, 22(5):945‐953. DOI: 10.1007/s10147‐017‐1147‐5.
[16] Kizer NT, Thaker PH, Gao F, et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy[J]. Cancer, 2011, 117(5):948‐956. DOI: 10.1002/cncr.25544.
[17] Kumar A, Tudu R, Singh R, et al. Dose‐volume analysis of acute gastrointestinal complications in cervical cancer undergoing definitive concurrent chemoradiation[J]. J Cancer Res Ther,2021,17(1):170‐173. DOI:10.4103/jcrt.JCRT_313_19.
2022, Vol. 31 
